Patients must have fewer than % marrow blasts within  days of consent.
Patient has one of the following: \r\n* Patients has previously untreated de novo AML and meets the criteria for AML with >= % bone marrow blasts as set out in the World Health Organization (WHO) Myeloid Neoplasm classification\r\n** Attempts to obtain bone marrow either by aspirate or biopsy must be made unless clinically prohibitive; in cases where it is clinically prohibitive, peripheral blood with an excess of % blasts and in which adequate flow cytometric and cytogenetics/FISH testing is feasible can be substituted for the marrow exam at diagnosis\r\n* Patients has cytopenias and/or bone marrow blasts but does not meet the criteria for the diagnosis of AML (WHO Myeloid Neoplasm classification) because of < % marrow blasts and meets the criteria for a diagnosis of myelodysplastic syndrome (MDS)\r\n* Patients has a history of transient myeloproliferative disorder (which may or may not have required chemotherapy intervention), who:\r\n* Are >  weeks since resolution of transient myeloproliferative disease (TMD) with >= % blasts, OR\r\n* Patients who have an increasing blast count (>= %) in serial bone marrow aspirates performed at least  weeks apart
In the event that the patients bone marrow blast count is >= % blasts, patients may be registered but should receive steroids for - days in order to reduce tumor burden prior to blinatumomab administration, as follows\r\n* Prephase treatment with dexamethasone (- mg/m^) for - days is required for patients with bone marrow blasts >= %, peripheral blood blasts ,/uL or higher, or elevated lactate dehydrogenase (LDH) suggesting rapidly progressive disease per investigator opinion\r\n** Pre-treatment should conclude at least  hours prior to the first dose of blinatumomab (although additional dexamethasone is automatically given as a pre-med prior to the first dose); at the time of first infusion of blinatumomab, the absolute peripheral blast count should be < ,/uL\r\n** Note: For the purposes of the study, day  of the cycle will be the first day of blinatumomab administration
Patients with MDS must have experienced treatment failure with at least one cycle of hypomethylating therapy or induction therapy and have ? % bone marrow blasts
Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)-refractory anemia with excess blasts (RAEB) (including chronic myelomonocytic leukemia [CMML] with excess blasts and MDS/myeloproliferative neoplasm [MPN] overlap syndrome) not in remission (defined as >= % blast in bone marrow or peripheral blood) prior to leukemia cell harvest; patients may receive additional cytoreductive therapy after leukemia cell harvest and before admission for transplant, , at the discretion of the treating physician; for patients with MDS-EB (< %blasts) or CMML-, it is recommended that they proceed directly to transplant after the harvest if donor is available; if there is an extended delay, interval therapy with HMA is allowed\r\n* Patients may or may not have active disease at the time of transplant conditioning, but for reduced intensity conditioning (RIC) candidates, it is strongly recommended that disease is cytoreduced such that the pre-transplant admission marrow shows:\r\n** < % blasts in a normocellular marrow (>= % cellularity), or\r\n** < % blasts in a hypocellular marrow (< % cellularity)
Acute lymphocytic leukemia (ALL): must have < % marrow blasts at the time of transplant
Myelodysplasia (MDS)/myeloproliferative syndrome (MPS): patients must have < % marrow blasts at time of transplant
During the  weeks prior to inclusion in study, subjects must have a baseline bone marrow examination including all of the following:\r\n* Cytomorphology to confirm bone marrow blasts;\r\n* Cytogenetics; AND\r\n* Eastern Cooperative Oncology Group (ECOG) status -
MDS - Marrow blasts must be > % and disease failed at least  prior hypomethylating agent
More than % blasts in bone marrow
In morphologic remission (< % marrow blasts) based on bone marrow (BM) biopsy performed +/-  days of day  post-transplantation
Patients must have IPSS score determined by cytogenetic analysis prior to randomization; patients with cytogenetic failure and =< % marrow blasts will be eligible
Participant with lymphoma must meet one of the following:\r\n* In first relapse, OR\r\n* Refractory to one or two courses of frontline induction therapy with measurable disease\r\n* Relapse in ALL is defined as the reappearance (in a patient who has previously achieved remission) of leukemic blasts in the bone marrow or peripheral blood\r\n** Should flow cytometric analyses suggest relapse (by the reappearance of a similar immunophenotype to the original leukemia) in the presence of < % blasts morphologically, a repeat bone marrow test is recommended to confirm relapse\r\n** Molecular or genetic relapse is characterized by the reappearance of a cytogenetic or molecular abnormality\r\n** Early relapse is defined as relapse on therapy or <  months after completion of frontline therapy; late relapse is defined as relapse occurring >=  months after completion of frontline therapy
Morphological disease in the bone marrow (? % blasts)
Bone marrow blasts of at least %
Patient must be diagnosed with acute leukemia in morphologic complete remission (CR or CR) or with MDS with no circulating blasts and with less than % blasts in the bone marrow
Patients who are currently undergoing or who previously underwent allogeneic HCT for \r\n* Acute myeloid leukemia (AML) of any subtype and any of the following:\r\n** With relapse or refractory disease (>= % marrow blasts by morphology, or circulating blasts, chloroma or granulocytic sarcoma) at the time of the pre-HCT work-up\r\n** With minimal/measurable residual disease (MRD: defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but < % marrow blasts by morphology, no circulating blasts) at the time of the pre-HCT work-up\r\n** With marrow aplasia or marked hypoplasia (bone marrow cellularity =< %) following chemotherapy for prior refractory AML at the time of the pre-HCT work-up\r\n** With relapse or refractory disease (>= % marrow blasts by morphology, or circulating blasts) at any time after HCT\r\n** With MRD at any time after HCT\r\n* Acute lymphoid leukemia (ALL) of any subtype and any of the following:\r\n** With relapse or refractory disease (>= % marrow blasts, or circulating blasts) at the time of the pre-HCT work-up\r\n** With MRD at the time of the pre-HCT work-up\r\n** With marrow aplasia or marked hypoplasia (bone marrow cellularity =< %) following chemotherapy for prior refractory ALL at the time of the pre-HCT work-up\r\n** With relapse or refractory disease (>= % marrow blasts, or circulating blasts) at any time after HCT\r\n** With MRD at any time after HCT\r\n* Biphenotypic/undifferentiated/any other type of acute leukemia and any of the following:\r\n** With relapse or refractory disease (defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but < % marrow blasts by morphology, no circulating blasts) at the time of the pre-HCT work-up\r\n** With MRD at the time of the pre-HCT work-up\r\n** With marrow aplasia or marked hypoplasia (bone marrow cellularity =< %) following chemotherapy for prior refractory acute leukemia at the time of the pre-HCT work-up\r\n** With relapse or refractory disease (>= % marrow blasts, or circulating blasts) at any time after HCT\r\n** With MRD at any time after HCT \r\n* Chronic myeloid leukemia with a history of blast crisis and \r\n** With relapse or refractory disease (>= % marrow blasts, or circulating blasts) at any time after HCT\r\n** With persistent rising minimal residual disease (defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but < % marrow blasts by morphology, no circulating blasts on >=  of two consecutive tests), refractory or ineligible for treatment with tyrosine kinase inhibitors at any time after HCT
Confirmation of measurable disease by blast % will be defined as a marrow blast percentage of > % by morphologic assessment on bone marrow examination; this criteria does not apply to myeloid sarcoma which must also show measurable lesion by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)/CT or photograph (i.e. Leukemia cutis); if marrow blasts of =< % blasts are enumerated the patient may be eligible only if there is clear (probable or definite) flow cytometric, cytogenetic or molecular aberrations (e.g. FLT-ITD, NPM, etc.) documenting relapse of the leukemia associated clone defined prior to HCT
Acute lymphocytic leukemia (ALL)  must have < % marrow blasts at the time of transplant
During the  weeks prior to inclusion in study, subjects must have a baseline bone marrow examination including all of the following:\r\n* Cytomorphology to confirm bone marrow blasts\r\n* Cytogenetics
> % bone marrow blasts at transplant if no history of AML and > % if had previous progression to AML (in a bone marrow biopsy  weeks prior to start of conditioning on study)
Patients with > % blasts on a day + bone marrow biopsy following + may either be enrolled or may be treated with a course of standard re-induction (e.g. + or similar) and then re-evaluated for response; eligible patients will meet any of the above criteria on a subsequent biopsy
Use of hydroxyurea is permitted to control blasts until day -
AML ONLY: AML with > % circulating blasts and > % bone marrow blasts
Acute leukemias: Must be in remission by morphology (< % blasts); NOTE: cytogenetic relapse or persistent disease without morphologic relapse is acceptable; also a small percentage of blasts that is equivocal between marrow regeneration versus (vs.) early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse
Diagnosis of relapsed or refractory AML, ALL, acute biphenotypic leukemia (assigned to the appropriate group by the treating physician and pathology/cytogenetics), advanced MDS defined as ?% bone marrow blasts, advanced MPN, MDS/MPN overlap syndrome with ?% bone marrow blasts, or advanced CML after failure of at least  TKIs
Diagnosis of relapsed or refractory AML, ALL, acute biphenotypic leukemia (assigned to the appropriate group by the treating physician and pathology/cytogenetics), advanced MDS defined as ?% bone marrow blasts, advanced MPN, MDS/MPN overlap syndrome with ?% bone marrow blasts, or advanced CML after failure of at least  TKIs
Isolated extramedullary leukemia without also meeting bone marrow criteria for acute leukemia (ie, ?% blasts in bone marrow aspirate)
Acute leukemias: Must be in remission by morphology (< % blasts); Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable; also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse
Subjects must have evaluable disease defined as > % blasts on marrow aspirate or biopsy, extramedullary disease (central nervous system [CNS] involvement is prohibited), or at least % blasts in the peripheral blood within  weeks prior to enrollment; Note: subjects with second or subsequent relapse are considered to have evaluable disease even without having > % marrow blasts if they are found to have persistent/recurrent disease-associated molecular or cytogenetic abnormalities at any time since their last cycle of intensive chemotherapy
Expectation that we can obtain about  million blasts from blood and/or marrow (e.g., circulating blast count of , or greater or cellular marrow with greater than or equal to % blasts)
Disease criteria: day  (+/- days) bone marrow aspiration or biopsy from the beginning of salvage DCIA: a. in complete morphologic remission with < % bone marrow blasts, or b. aplastic (< % bone marrow cellularity), and cytopenic with an absolute neutrophil count (ANC) less than ,/uL, or c. low disease burden with < % bone marrow (BM) blasts, with recovery of peripheral blood (PB) white blood cell (WBC) (ANC > ,/uL) and < % circulating blasts
Presence of less than % bone marrow blasts per bone marrow
Subjects must have either PB or BM blasts ?% at time of randomization.
Acute leukemias (includes T lymphoblastic lymphoma); remission is defined as < % blasts with no morphological characteristics of acute leukemia (e.g., Auer rods) in a bone marrow with > % cellularity, peripheral blood counts showing ANC > /ul, including patients in complete remission with incomplete platelet recovery (CRp); if the marrow has < % cellularity due to treatment related cytotoxicity, but still has < % blasts, an exception may be made to include this patient up to principal investigator (PI) discretion
Myeloproliferative disorder (MPD)\r\n* Life-threatening cytopenia(s), and/or red blood cell or platelet transfusion dependence\r\n* Patients with aplasia\r\n* Patients with excess blast less than or equal to % blasts in the bone marrow at work-up
Myelodysplastic syndrome (MDS): Any subtype; morphologic blasts must be less than % in an evaluable marrow (> % of normal cellularity for age); if blasts are % or more, patient requires induction chemotherapy pre-transplant to reduce blast count to less than %; patients who have a hypocellular marrow in the absence of excess blasts that is related to the underlying disease or as a result of treatment for MDS may also be eligible with the approval of the PI or designee
Biphenotypic or undifferentiated leukemia in any CR or if in st relapse must have < % blasts in bone marrow (BM)
Acute leukemias: must be in remission by morphology (< % blasts); note cytogenetic relapse or persistent disease without morphologic relapse is acceptable; also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse
Unless in post-chemotherapy and radioimmunoconjugated antibody induced aplasia, when he/she would be eligible, patients with acute leukemia in morphologic relapse/persistent disease defined as > % blasts in normocellular bone marrow OR any % blasts if blasts have unique morphologic markers (e.g. Auer rods) or associated cytogenetic markers that allows morphologic relapse to be distinguished are not eligible
Acute leukemias: must be in remission by morphology (=< % blasts); also a small percentage of blasts that is equivocal between marrow regeneration versus (vs.) early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse
<% blasts in marrow or blood at time of screening
<% bone marrow blasts.
More than % blasts in bone marrow
Presence of >= % abnormal blasts in the bone marrow
Other bone marrow failure syndromes or low grade (< % bone marrow blasts) MDS
Bone marrow blasts >% at randomization, OR
Circulating blasts < , (cytoreduction with hydroxyurea is allowed)
Acute lymphocytic leukemia- high risk CR as evidenced by high risk cytogenetics [eg t(;) or complex cytogenetic abnormalities] or >  cycle to obtain CR; second or greater CR; must be in remission by morphology; patients in morphologic relapse/persistent disease defined as > % blasts in normocellular bone marrow OR any % blasts if blasts have unique morphologic markers or associated cytogenetic markers that allows morphologic relapse to be distinguished are not eligible for arms  or ; note cytogenetic relapse or persistent disease without morphologic relapse is acceptable; also a small percentage of blasts that is equivocal between marrow regeneration vs early relapse is acceptable provided there are no associated cytogenetic markers consistent with relapse
Patients must have > % blasts in the bone marrow at the time of study enrollment
Newly diagnosed, histologically confirmed de novo AML (bone marrow blasts ? %), or
MDS: Patients must have < % marrow blasts; fewer than % marrow blasts must be documented by marrow examination within  weeks of initiation of conditioning
CMML: Patients with CMML who have not received myelosuppressive therapy must have < % marrow blasts; fewer than % marrow blasts must be documented by marrow examination within  weeks of initiation of conditioning; OR patients with CMML who have progressed beyond CMML and have received myelosuppressive chemotherapy must have < % marrow blasts; fewer than % marrow blasts must be documented by marrow examination within  weeks of initiation of conditioning
MPD: Patients must have < % marrow blasts; fewer than % marrow blasts must be documented by marrow examination within  weeks of initiation of conditioning
Atypical CML: Patients must have < % marrow blasts; fewer than % marrow blasts must be documented by marrow examination within  weeks of initiation of conditioning
Patients must have a history of relapsed/refractory CD+ B-ALL involving the marrow to be eligible for infusion of modified T cells; please note >= % blasts by morphology, fluorescent in situ hybridization (FISH)/cytogenetics, molecular translocation and/or flow cytometry constitutes a bone marrow relapse on this protocol \r\n* Patients must also fulfill one of the following criteria to be eligible for infusion of modified T cells:\r\n** Second or greater (>= ) relapse\r\n** Early first marrow relapse (st CR <  months)\r\n** Intermediate/late first marrow relapse (st CR >=  months from st CR) with poor initial response (>= % blasts by morphology and/or flow cytometry) following re-induction chemotherapy\r\n** Refractory disease\r\n** Ineligible for hematopoietic stem cell transplant (HSCT) as determined by the treating physician in consultation with the bone marrow transplant (BMT) service\r\n** Patient would not benefit from additional cytotoxic chemotherapy as determined by the treating physician
Patients must be in morphologic leukemia-free state (marrow blasts < %) without evidence of extramedullary disease within  days of HCT
CMML with % to % myeloblasts in the bone marrow and/or % to % blasts in the blood. OR Worl health organisation (WHO) Classifications:
RAEB  - defined as having % to % myeloblasts in the bone marrow and/or % to % blasts in the blood.
CMML  - defined as having % to % myeloblasts in the bone marrow and/or % to % blasts in the blood.
CMML  (Although CMML  is defined as having <% myeloblasts in the bone marrow and/or <% blasts in the blood, these participants may enroll only if bone marrow blasts >=%.
Active AML (bone marrow blasts >= % by morphology, staining, or flow) and/or presence of extramedullary disease
Patients with previously untreated primary AML who meet the customary criteria for AML with >= % bone marrow blasts as set out in the  World Health Organization (WHO) Myeloid Neoplasm Classification are eligible\r\n* Attempts to obtain bone marrow either by aspirate or biopsy must be made unless clinically prohibitive; in cases where it is clinically prohibitive, peripheral blood with an excess of % blasts and in which adequate flow cytometric and cytogenetics/fluorescent in situ hybridization (FISH) testing is feasible can be substituted for the marrow exam at diagnosis
Patients must have measureable disease as defined the presence of >= % blasts in bone marrow or extramedullary leukemia
Morphological disease in the bone marrow (? % blasts)
AML participants must have the following malignancy criteria: measurable and evaluable disease per tumor response criteria; ? % bone marrow blasts without alternate causality; and >  days since allogeneic stem cell transplantation relapse in participants relapsing after transplant
All patients must meet one of the qualifications as outlined below after prior HMA therapy:\r\n* Relapse after CR/CRi or partial remission (PR) -  or more of the following:\r\n** Return to pretreatment bone marrow blast percentage (for initial PR)\r\n** Reappearance of bone marrow blasts (> %) following initial CR/CRi\r\n* Disease progression\r\n** For patients with % to % blasts: a % or more increase to more than % blasts\r\n** For patients with > % blasts: a % or more increase to more than % blasts\r\n* Refractory disease\r\n** No evidence of a response (CR, CRi, PR) following, at least,  cycles of hypomethylating agent
Subjects must have a diagnosis of relapsed or refractory ALL with ? % blasts in the bone marrow (M or M disease), with or without extramedullary disease. -To be eligible, subjects must have had  or more prior therapeutic attempts, defined as:
Disease refractory or relapsed (defined as the reappearance of > % blasts in the bone marrow).
Any acute leukemia (including prior myelodysplasia or CML blast crisis) with morphologic relapse or persistent disease >= % blasts in the bone marrow (BM), or doubling of the blasts in the blood in the  weeks preceding admission, or need for hydroxyurea in the  weeks prior to admission, or uncontrolled extra-medullary disease
<% blasts in blood or marrow at screening
Patients with advanced MDS must have < % marrow blasts prior to receiving conditioning with TLI/ATG; less than % marrow blasts must be documented by marrow examination within  month of starting conditioning; if necessary, a cytoreductive regimen will be determined by referring centers
Patients with evolution to AML are required to be in a morphologic leukemia free-state with blasts < %
Patients with MPD must have < % marrow blasts prior to receiving conditioning with TLI/ATG; less than % marrow blasts must be documented by marrow examination within  month of starting conditioning; if necessary, a cytoreductive regimen will be determined by referring centers
Patients with evolution to AML are required to be in a morphologic leukemia-free state with blasts less than % in a marrow aspirate; presence of residual dysplastic features following cytoreductive therapy is acceptable
Therapy-related myeloid neoplasms:\r\n* Patients with therapy related-MDS (t-MDS) must have < % marrow blasts prior to receiving conditioning with TLI/ATG; less than % marrow blasts must be documented by marrow examination within  month of starting conditioning; if necessary, a cytoreductive regimen will be determined by referring centers
Patients with t-AML are required to be in a morphologic leukemia free-state with blasts < %
% blasts in bone marrow
Patients must have obtained a complete remission with chemotherapy defined by the absence of circulating blasts, and less than % blasts on bone marrow examination following hematopoietic recovery
Acute lymphocytic leukemia (ALL) must have < % marrow blasts at the time of HCT
Patients with accelerated phase chronic myelogenous leukemia may have =< % blasts in the peripheral smear or bone marrow at study entry
Patients must have >= % blasts by morphology in the bone marrow OR molecular evidence of at least .% leukemic blasts in the bone marrow
Morphological evidence of disease in bone marrow (at least % blasts)
Patients with a diagnosis of myelodysplastic syndrome with >= % bone marrow blasts with no response or progression of disease after at least  cycles of a hypomethylating agent (-azacytidine or decitabine)
Relapse in ALL is defined as the reappearance (in a patient who has previously achieved remission) of leukemic blasts in the bone marrow\r\n* Should flow cytometric analyses suggest relapse (by the reappearance of a similar immunophenotype to the original leukemia) in the presence of < % blasts morphologically, a repeat bone marrow test is recommended to confirm relapse\r\n* Molecular or genetic relapse is characterized by the reappearance of a cytogenetic or molecular abnormality
Patients must have a diagnosis of acute lymphoblastic leukemia (ALL) with ? % blasts in the bone marrow (M), with or without extramedullary disease.
Patients with T-cell ALL must have greater than % blasts in the bone marrow with or without extramedullary disease.
Patients must have received at least one prior chemotherapy regimen for their AML and they may have received any type of chemotherapy; disease relapse or the presence of refractory disease must be documented by bone marrow examination demonstrating > % blasts in the bone marrow not attributable to another cause; administration of hydrea to control high white blood cell (WBC) count is permitted
Patients with AML in the first morphologic relapse as defined by >= % reappearance of leukemia blasts in the bone marrow not attributable to any other cause who have not yet received chemotherapy for the current relapse
Non-M acute myeloid leukemia (AML) with the presence of residual disease in the bone marrow on day - post induction (or re-induction) chemotherapy; day - residual disease is defined in this study as the presence of more than  % blasts in the marrow in patients, presence of between -% blasts cells that are not in cluster in hypocellular marrow is ambiguous and bone marrow biopsy should be repeated in - days
< % blasts in blood or marrow at screening, except if measurable extramedullary AML is confirmed
Blasts in PB < % prior to study enrollment
Leukemic transformation (> % blasts in PB or bone marrow [BM] any time prior to hematopoietic cell transplantation [HCT])
Patients must have > % leukemic blasts in the bone marrow;
Greater than % blasts in bone marrow
Relapsed or refractory (resistant) disease, as defined by standard criteria:\r\n* Relapsed: bone marrow blasts >= %; reappearance of blasts in the blood; development of extramedullary disease\r\n* Refractory (resistant): failure to achieve CR or CRi in patients who survive >=  days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination
Transformed disease (bone marrow blasts are permitted; however, transformed disease indicating leukemic involvement is not permitted)
Leukemic relapse or disease progression: Patients with > % leukemic blasts in the bone marrow will not be eligible for DLI; cytoreduction with chemotherapy is permissible to reduce blast count to =< %
Patients must have >= % blasts in the bone marrow
Diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) with < % blasts in the bone marrow (M) by morphology and that meets one of the following criteria:\r\n* Flow cytometric evidence of minimal residual disease (MRD) (>= .% leukemic blasts for ALL or < % leukemic blasts for AML detected in the bone marrow) OR\r\n* Molecular/cytogenetic evidence of disease (fluorescence in situ hybridization [FISH] or polymerase chain reaction [PCR] methodology) performed within  days AND\r\n* With the intent of going on to an allogeneic hematopoietic cell transplantation (allo-HCT) independent of this study
Patients must have documented hypoplasia from the bone marrow aspiration and biopsy  days +/-  days from the initiation of cytarabine treatment schedule (defined as < % blasts and < % cellularity)
Acute Leukemias: Must be in remission by morphology (< % blasts); Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable; also a small percentage of blasts that is equivocal between marrow regeneration versus early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse
Patients with acute leukemia in morphologic complete remission with or without hematologic recovery or with myelodysplasia (MDS) with no circulating blasts and with less than % blasts in the bone marrow. Patients with CMML must have a WBC count ? , cells/L and < % blasts in the marrow. Patients with ? % blasts due to a regenerating marrow must contact the protocol chairs for review.
Subjects with acute leukemia, chronic myelogenous leukemia, or myelodysplasia must have no circulating blasts and < % blasts of the bone marrow.
Less than or equal to % blasts on bone marrow examination within  days of starting conditioning
Patients with acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than % blasts in the bone marrow
Acute lymphocytic leukemia (ALL)  must have < % marrow blasts at the time of transplant
Myelodysplasia (MDS)/myeloproliferative syndrome (MPS)  Patients must have < % marrow blasts at time of transplant
Acute lymphoblastic leukemia (ALL) in first or higher remission (< % blasts in the bone marrow)
Acute leukemias: Must be in remission by morphology (=< % blasts); also a small percentage of blasts that is equivocal between marrow regeneration versus early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse
Pre-injectable HMA (HYPOMETHYLATING AGENT) baseline bone marrow myeloblasts: a. Less than %: ? % increase to ? % blasts b. ? %: ? % increase to ? % blasts Note: ? % blasts is considered AML (ACUTE MYELOID LEUKEMIAT) per FAB (FRENCH-AMERICAN BRITISH)classification. Subjects known to have ? % blasts are not eligible for inclusion in this study. RECOG (Eastern Cooperative Oncology Group) nizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment bone marrow blast counts up to % on the screening bone marrow examination to be considered for inclusion. Assessment may be made according to local bone marrow examination to facilitate enrollment of eligible subjects into the treatment phase of the study.
Acute myelogenous leukemia (AML (ACUTE MYELOID LEUKEMIA) - FAB (FRENCH-AMERICAN-BRITISH) classification: ? % blasts in bone marrow). Subjects known to have ? % blasts are not eligible for inclusion in this study. Recognizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment (screening/baseline) bone marrow blast counts up to % to be considered for inclusion.
Patients with acute leukemia, chronic myelogenous leukemia, myeloproliferative disorder and myelodysplasia with no circulating blasts and with less than % blasts in the bone marrow within  weeks of the start of transplant conditioning regimen
Patients with acute leukemia, chronic myelogenous leukemia or myelodysplasia with no circulating blasts and with less than % blasts in the bone marrow.
Patients must have obtained a complete remission with chemotherapy defined by the absence of circulating blasts, and less than % blasts on bone marrow examination following hematopoietic recovery